NEW YORK, March 02, 2017 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (OTCQB:TYMI), a specialty biotechnology company developing cancer therapeutics targeted at multiple tumor types, today announced the addition of Paul L. Sturman, a seasoned pharmaceutical executive with 30 years in the consumer health industry at Pfizer, Johnson & Johnson and Warner Lambert, to the company’s board of directors.
“As Tyme transforms from being an early-stage biotech company to a more fully integrated one, Paul’s expertise in managing complex organizations and building corporate culture will be invaluable,” said CEO Steve Hoffman. “Throughout his career in large pharma, Paul has a track record of consistently delivering growth in revenue, profitability and market share, underscored by a lifelong commitment to improving quality of healthcare and access through education. We look forward to his extensive experience and board leadership as we move forward.”
Mr. Sturman has worked in the healthcare industry in a variety of leadership positions. At Pfizer, Mr. Sturman ran the Global Consumer Healthcare division, one of the largest over-the-counter healthcare products companies in the world. He also previously served as President of J&J’s North American Consumer Health division as well as numerous leadership roles in marketing, brand, and sales management with Warner Lambert. He is a member of the Board of Trustees of the Foundation for Morristown Medical Center, one of “America’s Top 50 Hospitals,” which works to advance healthcare for patients by preserving and expanding programs and services in patient care, clinical research, medical and public health education, and preventive medicine.
About Tyme
Tyme Technologies is developing a novel first-in-class therapy, SM-88, that is designed to use cancer’s unusual metabolism to selectively break down the cellular defenses of tumors, leading to tumor cell death. Through clinical trials and expanded access programs, SM-88 has been used in over 84 individuals and shown a clinical response in thirteen cancer types. In its initial Phase I trial for end-stage, metastatic cancer patients, SM-88 treatment resulted in a median overall survival of 26 months, with 32% of patients alive at the end of the three year evaluation period without any drug-related serious adverse events. The Company is currently conducting a Phase Ib/II trial in prostate cancer in addition to ongoing collaborations with the Mayo Clinic, Mount Sinai, the Albert Einstein College of Medicine and other institutions. For more information, visit our website: www.tymeinc.com.
Forward-Looking Statements/Disclosure Notice
In addition to historical information, this press release contains forward-looking statements that involve substantial risks and uncertainties. Such forward-looking statements within this press release include, without limitation, statements regarding our drug candidates (including SM-88), our drug development plans and strategies, our completed and planned clinical trials and the therapeutic design and mechanisms of our drug candidates; and readers can identify forward-looking statements by sentences or passages involving the use of terms such as “anticipates,” “believes,” “designed,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “would” and similar expressions intended to identify forward-looking statements. The forward-looking statements contained in this press release are based on management’s current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of Tyme’s control. These statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance or achievements to be materially different from any historical results and future results, performances or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, uncertainties inherent in research and development, including the ability to achieve clinical study start and completion dates; the possibility of unfavorable study results, including unfavorable new clinical data and additional analyses of existing data; risks associated with early, initial data, including the risk that the final Phase 1b data analysis, final results of additional clinical trials, or both, may be different from the preliminary data analysis and may not support further clinical development; whether and when any applications or other submissions for SM-88 may be filed with regulatory authorities; whether and when regulatory authorities may approve any applications or submissions; decisions by regulatory authorities regarding labeling and other matters that could affect commercial availability of SM-88; competitive developments; and the factors described in the section captioned “Risk Factors” of Tyme’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission on March 30, 2016 (available at www.sec.gov).
The information contained in this press release is as of January 31, 2017 and Tyme assumes no obligation to update forward-looking statements contained in this release as a result of future events or developments.